CHRISTOS BOVETAS: Open Payments
NPI 1487740262 · CORONA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,116 in 66 payments from 13 companies in 2025. Trend: 2023 $1,114 · 2024 $1,368 · 2025 $1,116
Food & beverage: $1,116
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $285 |
| Amgen Inc. | 19 | $252 |
| ABBVIE INC. | 20 | $166 |
| Novo Nordisk Inc | 5 | $123 |
| Abbott Laboratories | 3 | $66 |
| GlaxoSmithKline, LLC. | 2 | $52 |
| Lilly USA, LLC | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| Dexcom, Inc. | 1 | $25 |
Products named: AIRSUPRA, OTEZLA, QULIPTA, FREESTYLE LIBRE 3, TRELEGY ELLIPTA, Ozempic, Wegovy, LINZESS.
Industry payments across CA — which companies pay providers there.
